董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Avraham Ben Tzvi | 男 | Director | 52 | 2.44万美元 | 未持股 | 2023-05-18 |
| Joseph A. Akers | 男 | Director | 77 | 7.14万美元 | 未持股 | 2023-05-18 |
| M. David MacFarlane | 男 | Director | 82 | 7.01万美元 | 未持股 | 2023-05-18 |
| Katherine Beebe DeVarney | 女 | President and Chief Operating Officer,Director | 62 | 36.23万美元 | 未持股 | 2023-05-18 |
| Avraham Ben Tzvi | 男 | Director | 52 | 未披露 | 未持股 | 2023-05-18 |
| Peter L. Chasey | 男 | Director | 49 | 2.06万美元 | 未持股 | 2023-05-18 |
| Eric Greenberg | 男 | Director | 58 | 2.25万美元 | 未持股 | 2023-05-18 |
| David Lazar | 男 | Director,Chief Executive Officer | 32 | 15.23万美元 | 未持股 | 2023-05-18 |
| Matthew C. McMurdo | 男 | Director | 51 | 1.88万美元 | 未持股 | 2023-05-18 |
| David Natan | 男 | Director | 69 | 2.34万美元 | 未持股 | 2023-05-18 |
| James R. McNab, Jr. | 男 | Director | 78 | 7.14万美元 | 未持股 | 2023-05-18 |
| Marc Rubin | 男 | Executive Chairman | 67 | 42.62万美元 | 未持股 | 2023-05-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Katherine Beebe DeVarney | 女 | President and Chief Operating Officer,Director | 62 | 36.23万美元 | 未持股 | 2023-05-18 |
| David Lazar | 男 | Director,Chief Executive Officer | 32 | 15.23万美元 | 未持股 | 2023-05-18 |
董事简历
中英对照 | 中文 | 英文- Avraham Ben Tzvi
-
Avraham Ben Tzvi，2014年4月起，担任本公司的法律总顾问、企业秘书。2009-2014，他是Yigal Arnon & Co.的律师，除了其它企业和商业工作，他为公司和承销商提供服务，包括在美国上市的以色列公司发行、SEC相关文件的填制。2009年之前，他金融服务、制造、软件开发行业，担任各种职务，涉及业务开发、企业财务、银行事务。他在纽约的 Yeshiva University获得经济学士学位，在以色列Hod Hasharon的Sha'arei Mishpat College of Law 获得法律学士学位。
Avraham Ben Tzvi the Group’s chief legal officer, has served as the Kitov general counsel since November 2015 and was appointed as the Kitov company secretary in December 2015. Mr. Ben-Tzvi previously served as general counsel and company secretary at Medigus Ltd., a publicly traded minimally invasive endosurgical tools medical device and miniaturized imaging equipment company NASDAQ/TASE:MDGS, from April 2014 until November 2015. Prior to that he served as an attorney at Yigal Arnon & Co. from 2009 to 2014 where, among other corporate and commercial work, he advised companies and underwriters on various offerings by Israeli companies listing in the U.S. and/or Israel and on various SEC and Israeli related securities law filings. Prior to 2009 Mr. Ben-Tzvi worked in a number of business development, corporate finance and banking roles at companies in the financial services, manufacturing and software development industries. Mr. Ben-Tzvi holds a BA in Economics from Yeshiva University in New York and an Ll.B from Sha’arei Mishpat College of Law in Hod Hasharon, Israel. - Avraham Ben Tzvi，2014年4月起，担任本公司的法律总顾问、企业秘书。2009-2014，他是Yigal Arnon & Co.的律师，除了其它企业和商业工作，他为公司和承销商提供服务，包括在美国上市的以色列公司发行、SEC相关文件的填制。2009年之前，他金融服务、制造、软件开发行业，担任各种职务，涉及业务开发、企业财务、银行事务。他在纽约的 Yeshiva University获得经济学士学位，在以色列Hod Hasharon的Sha'arei Mishpat College of Law 获得法律学士学位。
- Avraham Ben Tzvi the Group’s chief legal officer, has served as the Kitov general counsel since November 2015 and was appointed as the Kitov company secretary in December 2015. Mr. Ben-Tzvi previously served as general counsel and company secretary at Medigus Ltd., a publicly traded minimally invasive endosurgical tools medical device and miniaturized imaging equipment company NASDAQ/TASE:MDGS, from April 2014 until November 2015. Prior to that he served as an attorney at Yigal Arnon & Co. from 2009 to 2014 where, among other corporate and commercial work, he advised companies and underwriters on various offerings by Israeli companies listing in the U.S. and/or Israel and on various SEC and Israeli related securities law filings. Prior to 2009 Mr. Ben-Tzvi worked in a number of business development, corporate finance and banking roles at companies in the financial services, manufacturing and software development industries. Mr. Ben-Tzvi holds a BA in Economics from Yeshiva University in New York and an Ll.B from Sha’arei Mishpat College of Law in Hod Hasharon, Israel.
- Joseph A. Akers
-
Joseph A. Akers，曾在Bayer Corporation、Bayer Healthcare 及某些关联实体担任过各种职务，包括：血液/心脏病业务部总裁，2004-2007；商业与企业服务总裁、首席执行官，2002年7月至2003年；执行副总裁、首席行政与财务官，1999年至2002年7月。他在University of California at Berkeley获得营销学士学位、财务方向的工商管理硕士学位。
Joseph A. Akers,was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities until his retirement in 2008, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive officer of Bayer Business and Corporate Services from July 2002 through 2003 and executive vice president and chief administrative and financial officer from 1999 to July 2002. Mr. Akers received a B.S. in marketing and an M.B.A. in finance from the University of California at Berkeley. Mr. Akers is not standing for re-election as a director at the Annual Meeting. - Joseph A. Akers，曾在Bayer Corporation、Bayer Healthcare 及某些关联实体担任过各种职务，包括：血液/心脏病业务部总裁，2004-2007；商业与企业服务总裁、首席执行官，2002年7月至2003年；执行副总裁、首席行政与财务官，1999年至2002年7月。他在University of California at Berkeley获得营销学士学位、财务方向的工商管理硕士学位。
- Joseph A. Akers,was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities until his retirement in 2008, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive officer of Bayer Business and Corporate Services from July 2002 through 2003 and executive vice president and chief administrative and financial officer from 1999 to July 2002. Mr. Akers received a B.S. in marketing and an M.B.A. in finance from the University of California at Berkeley. Mr. Akers is not standing for re-election as a director at the Annual Meeting.
- M. David MacFarlane
-
M. David MacFarlane，1989年起，担任Genentech, Inc. 的副总裁、监管事务负责总监，直到1999年8月退休。加入Genentech, Inc. 之前，他在Glaxo Inc.担任过各种职务，最后的是监管事务副总裁。
M. David MacFarlane,served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. Prior to joining Genentech, Inc., he served in various positions with Glaxo Inc., last as Vice President of Regulatory Affairs. Dr. MacFarlane is not standing for re-election as a director at the Annual Meeting. - M. David MacFarlane，1989年起，担任Genentech, Inc. 的副总裁、监管事务负责总监，直到1999年8月退休。加入Genentech, Inc. 之前，他在Glaxo Inc.担任过各种职务，最后的是监管事务副总裁。
- M. David MacFarlane,served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. Prior to joining Genentech, Inc., he served in various positions with Glaxo Inc., last as Vice President of Regulatory Affairs. Dr. MacFarlane is not standing for re-election as a director at the Annual Meeting.
- Katherine Beebe DeVarney
-
Katherine Beebe DeVarney于2007年2月加入泰坦，自2020年10月起担任总裁兼首席运营官。此前，她曾担任首席科学官。她自2019年12月起担任董事会成员。Beebe Devarney博士在我们公司工作的13年中，担任过各种科学和医疗研究与开发职务，主要负责监督我们的产品研究与开发、监管事务和医疗事务。她拥有25年的制药行业神经科学家经验，包括任职SmithKline Beecham公司、GlaxoSmithKline公司、Merck公司、Corcept Therapeutics公司，并不断被提拔。在她的制药职业生涯之前，Beebe Devarney博士是一位以医院为基础的临床医生，在学术医学领域工作了10年。她在乔治梅森大学（George Mason University）获得临床神经心理学博士学位，并在研究生院和宾夕法尼亚大学（University of Pennsylvania）完成了两年的博士后奖学金。
Katherine Beebe DeVarney,joined Titan in February 2007 and currently serves as Titan Pharmaceuticals, Inc. President and Chief Operating Officer since October 2020. She has been a member of the Board since December 2019. During her 15 years with Titan Pharmaceuticals, Inc. , she has served in various scientific and medical research and development capacities, with primary responsibility for oversight of Titan Pharmaceuticals, Inc. product research and development, Regulatory Affairs, and Medical Affairs. Dr. Beebe DeVarney has 24 years of experience as a Neuroscientist in the pharmaceutical industry, including positions of increasing responsibility with SmithKline Beecham, GlaxoSmithKline, Merck, and Corcept Therapeutics. Prior to her pharmaceutical career, Dr. Beebe DeVarney was a hospital-based clinician and worked in academic medicine for 10 years. She received her Ph.D. in Clinical Neuropsychology from George Mason University, and completed a two-year post-doctoral fellowship at Graduate Hospital and the University of Pennsylvania. - Katherine Beebe DeVarney于2007年2月加入泰坦，自2020年10月起担任总裁兼首席运营官。此前，她曾担任首席科学官。她自2019年12月起担任董事会成员。Beebe Devarney博士在我们公司工作的13年中，担任过各种科学和医疗研究与开发职务，主要负责监督我们的产品研究与开发、监管事务和医疗事务。她拥有25年的制药行业神经科学家经验，包括任职SmithKline Beecham公司、GlaxoSmithKline公司、Merck公司、Corcept Therapeutics公司，并不断被提拔。在她的制药职业生涯之前，Beebe Devarney博士是一位以医院为基础的临床医生，在学术医学领域工作了10年。她在乔治梅森大学（George Mason University）获得临床神经心理学博士学位，并在研究生院和宾夕法尼亚大学（University of Pennsylvania）完成了两年的博士后奖学金。
- Katherine Beebe DeVarney,joined Titan in February 2007 and currently serves as Titan Pharmaceuticals, Inc. President and Chief Operating Officer since October 2020. She has been a member of the Board since December 2019. During her 15 years with Titan Pharmaceuticals, Inc. , she has served in various scientific and medical research and development capacities, with primary responsibility for oversight of Titan Pharmaceuticals, Inc. product research and development, Regulatory Affairs, and Medical Affairs. Dr. Beebe DeVarney has 24 years of experience as a Neuroscientist in the pharmaceutical industry, including positions of increasing responsibility with SmithKline Beecham, GlaxoSmithKline, Merck, and Corcept Therapeutics. Prior to her pharmaceutical career, Dr. Beebe DeVarney was a hospital-based clinician and worked in academic medicine for 10 years. She received her Ph.D. in Clinical Neuropsychology from George Mason University, and completed a two-year post-doctoral fellowship at Graduate Hospital and the University of Pennsylvania.
- Avraham Ben Tzvi
-
Avraham Ben Tzvi是ABZ律师事务所的创始人，这是一家以色列精品律师事务所，专门为上市公司和私营公司、投资与证券法、商法与合同以及各种民法事务提供外包总法律顾问服务，他于2017年1月成立了该事务所。Ben-Tzvi先生曾于2015年11月至2020年4月担任Purple Biotech Ltd.（前Kitov Pharma Ltd.）（NASDAQ/TASE：PPBT）的首席法务官和总法律顾问，该公司是一家临床阶段的公司，致力于开发一流疗法，以克服肿瘤免疫逃避和耐药性。在此之前，Ben-Tzvi先生于2014年4月至2015年11月担任Medigus有限公司（NASDAQ/TASE：MDGS）的总法律顾问和公司秘书，该公司是一家微创内外科手术工具医疗设备和小型成像设备公司。在此之前，他曾在以色列一家领先的国际律师事务所担任律师，除其他公司和商业工作外，他还就在美国上市的以色列公司的各种发行以及与美国证交会相关的各种文件为公司和承销商提供咨询。在成为律师之前，Ben-Tzvi先生曾在金融服务、锂电池制造和软件开发行业的公司担任多个业务发展、企业融资和银行职务。Ben-Tzvi先生拥有纽约Yeshiva大学的经济学学士学位和以色列Hod HaSharon的Sha'arei Mishpat法学院的法学学士学位。Ben-Tzvi先生是Israel Bar协会的成员，也是以色列司法部颁发的公证人执照。
Avraham Ben Tzvi,is the Founder of ABZ Law Office, a boutique Israeli law firm specializing in outsourced general counsel services for publicly traded as well as private companies and corporations, Investments & Securities Laws, Commercial Law & Contracts and various civil law matters, which he established in January 2017. Mr. Ben-Tzvi served as Chief Legal Officer and General Counsel of Purple Biotech Ltd. (formerly Kitov Pharma Ltd.) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, from November 2015 until April 2020. Prior to that, Mr. Ben-Tzvi served as General Counsel and Company Secretary at Medigus Ltd. (NASDAQ/TASE: MDGS), a minimally invasive endosurgical tools medical device and miniaturized imaging equipment company, from April 2014 until November 2015. Prior to that he served as an attorney at one of Israel's leading international law firms where, amongst other corporate and commercial work, he advised companies and underwriters on various offerings by Israeli companies listing in the US and on various SEC related filings. Prior to becoming a lawyer, Mr. Ben-Tzvi worked in a number of business development, corporate finance and banking roles at companies in the financial services, lithium battery manufacturing and software development industries. Mr. Ben-Tzvi holds a B.A., magna cum laude, in Economics from Yeshiva University in New York and an LL.B., magna cum laude with Honors from Sha'arei Mishpat College of Law in Hod HaSharon, Israel. Mr. Ben-Tzvi is a member of the Israel Bar Association, and is also licensed as a Notary by the Israeli Ministry of Justice. - Avraham Ben Tzvi是ABZ律师事务所的创始人，这是一家以色列精品律师事务所，专门为上市公司和私营公司、投资与证券法、商法与合同以及各种民法事务提供外包总法律顾问服务，他于2017年1月成立了该事务所。Ben-Tzvi先生曾于2015年11月至2020年4月担任Purple Biotech Ltd.（前Kitov Pharma Ltd.）（NASDAQ/TASE：PPBT）的首席法务官和总法律顾问，该公司是一家临床阶段的公司，致力于开发一流疗法，以克服肿瘤免疫逃避和耐药性。在此之前，Ben-Tzvi先生于2014年4月至2015年11月担任Medigus有限公司（NASDAQ/TASE：MDGS）的总法律顾问和公司秘书，该公司是一家微创内外科手术工具医疗设备和小型成像设备公司。在此之前，他曾在以色列一家领先的国际律师事务所担任律师，除其他公司和商业工作外，他还就在美国上市的以色列公司的各种发行以及与美国证交会相关的各种文件为公司和承销商提供咨询。在成为律师之前，Ben-Tzvi先生曾在金融服务、锂电池制造和软件开发行业的公司担任多个业务发展、企业融资和银行职务。Ben-Tzvi先生拥有纽约Yeshiva大学的经济学学士学位和以色列Hod HaSharon的Sha'arei Mishpat法学院的法学学士学位。Ben-Tzvi先生是Israel Bar协会的成员，也是以色列司法部颁发的公证人执照。
- Avraham Ben Tzvi,is the Founder of ABZ Law Office, a boutique Israeli law firm specializing in outsourced general counsel services for publicly traded as well as private companies and corporations, Investments & Securities Laws, Commercial Law & Contracts and various civil law matters, which he established in January 2017. Mr. Ben-Tzvi served as Chief Legal Officer and General Counsel of Purple Biotech Ltd. (formerly Kitov Pharma Ltd.) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, from November 2015 until April 2020. Prior to that, Mr. Ben-Tzvi served as General Counsel and Company Secretary at Medigus Ltd. (NASDAQ/TASE: MDGS), a minimally invasive endosurgical tools medical device and miniaturized imaging equipment company, from April 2014 until November 2015. Prior to that he served as an attorney at one of Israel's leading international law firms where, amongst other corporate and commercial work, he advised companies and underwriters on various offerings by Israeli companies listing in the US and on various SEC related filings. Prior to becoming a lawyer, Mr. Ben-Tzvi worked in a number of business development, corporate finance and banking roles at companies in the financial services, lithium battery manufacturing and software development industries. Mr. Ben-Tzvi holds a B.A., magna cum laude, in Economics from Yeshiva University in New York and an LL.B., magna cum laude with Honors from Sha'arei Mishpat College of Law in Hod HaSharon, Israel. Mr. Ben-Tzvi is a member of the Israel Bar Association, and is also licensed as a Notary by the Israeli Ministry of Justice.
- Peter L. Chasey
-
Peter L. Chasey，自2005年创立以来，目前担任Chasey Law Offices的所有者，这是一家专门从事个人诉讼、商业诉讼和商业法的律师事务所。在其职业生涯的早期，Chasey先生曾担任世界上最大的保险公司之一的工作人员法律顾问，为被保险企业的一般索赔辩护，并担任过土地测量师。Chasey先生拥有圣迭戈大学政治学和政府管理学士学位和圣迭戈大学法学院法学博士学位。
Peter L. Chasey,currently serves as the Owner of Chasey Law Offices, a law practice specializing in personal litigation, business litigation and commercial law, since founding the practice in 2005. Earlier in his career, Mr. Chasey served as staff counsel for one of the largest insurance companies in the world defending general claims against insured businesses and also served as a land surveyor. Mr. Chasey holds a B.S. in Political Science and Government from the University of San Diego and a J.D. from the University of San Diego School of Law. - Peter L. Chasey，自2005年创立以来，目前担任Chasey Law Offices的所有者，这是一家专门从事个人诉讼、商业诉讼和商业法的律师事务所。在其职业生涯的早期，Chasey先生曾担任世界上最大的保险公司之一的工作人员法律顾问，为被保险企业的一般索赔辩护，并担任过土地测量师。Chasey先生拥有圣迭戈大学政治学和政府管理学士学位和圣迭戈大学法学院法学博士学位。
- Peter L. Chasey,currently serves as the Owner of Chasey Law Offices, a law practice specializing in personal litigation, business litigation and commercial law, since founding the practice in 2005. Earlier in his career, Mr. Chasey served as staff counsel for one of the largest insurance companies in the world defending general claims against insured businesses and also served as a land surveyor. Mr. Chasey holds a B.S. in Political Science and Government from the University of San Diego and a J.D. from the University of San Diego School of Law.
- Eric Greenberg
-
埃里克格林伯格，作为对冲基金的交易员和投资组合经理，他的专长领域包括交易策略的开发、投资组合管理和交易结构。格林伯格先生是Blink Charging Co.（纳斯达克股票代码：BLNK）的联合创始人，该公司是电动汽车充电基础设施行业的领导者。此外，格林伯格还为生命科学、金融科技、互联网平台等多个行业的公司提供投资者关系和数字营销服务。格林伯格拥有巴鲁克学院金融学学士学位和巴鲁克学院齐克林商学院金融学工商管理硕士学位。
Eric Greenberg,As a trader and portfolio manager at hedge funds, his areas of expertise included the development of trading strategies, portfolio management and deal structuring. Mr. Greenberg was Co-Founder of Blink Charging Co. (NASDAQ: BLNK), a leader in the EV charging infrastructure industry. In addition, Mr. Greenberg provides investor relation and digital marketing services for companies across a variety of industries, such as life sciences, fintech, internet platforms and others. Mr. Greenberg holds a B.B.A in Finance from Baruch College and an M.B.A. in Finance from Baruch College Zicklin School of Business. - 埃里克格林伯格，作为对冲基金的交易员和投资组合经理，他的专长领域包括交易策略的开发、投资组合管理和交易结构。格林伯格先生是Blink Charging Co.（纳斯达克股票代码：BLNK）的联合创始人，该公司是电动汽车充电基础设施行业的领导者。此外，格林伯格还为生命科学、金融科技、互联网平台等多个行业的公司提供投资者关系和数字营销服务。格林伯格拥有巴鲁克学院金融学学士学位和巴鲁克学院齐克林商学院金融学工商管理硕士学位。
- Eric Greenberg,As a trader and portfolio manager at hedge funds, his areas of expertise included the development of trading strategies, portfolio management and deal structuring. Mr. Greenberg was Co-Founder of Blink Charging Co. (NASDAQ: BLNK), a leader in the EV charging infrastructure industry. In addition, Mr. Greenberg provides investor relation and digital marketing services for companies across a variety of industries, such as life sciences, fintech, internet platforms and others. Mr. Greenberg holds a B.B.A in Finance from Baruch College and an M.B.A. in Finance from Baruch College Zicklin School of Business.
- David Lazar
-
David Lazar，自2018年2月起担任Custodian Ventures LLC（一家专门通过托管协助陷入困境的上市公司的公司）和Activist Investing LLC（一家积极管理的投资基金）的首席执行官。此前，Lazar先生于2012年7月至2018年4月担任精品咨询公司Zenith Partners International Inc.的管理合伙人。在担任Custodian Ventures LLC的首席执行官期间，Lazar先生成功地担任了多个行业众多上市公司的托管人，包括但不限于C2E Energy， Inc.(OTCMKTS: OOGI),China Botanic Pharmaceutical Inc.(OTCMKTS: CBPI),One 4 Art Ltd.,Romulus Corp.,Moveix, Inc.,Arax Holdings Corp.(OTCMKTS: ARAT),ESP Resources,Inc.(OTCMKTS: ESPIQ),Adorbs,Inc.,Exobox Technologies Corp. （OTCMKTS: CBPI）。EXBX)、Petrone Worldwide（OTCMKTS: PFWIQ）、Superbox（OTCMKTS: SBOX）、Sino Green Land corp（OTCMKTS: SGLA）、SIPP International Industries（OTCMKTS: SIPN）、Cereplast（OTCMKTS: CERPQ）、Energy 1 corp（OTCMKTS: EGOC）、ForU Holdings（OTCMKTS: ForU）、中国盐源宇辉国民教育集团（OTCMKTS: YYYH）、Pan Global corp （OTCMKTS: PGLO）、Shengtang International （OTCMKTS: SHNL）、Alternaturals,Inc(OTCMKTS:SBOX)：ANAS)、美国回收工业公司（OTCMKTS:USRI）、Tele集团公司、Xenoics控股公司（OTCMKTS: XNNHQ）、Richland资源国际集团公司（OTCMKTS: RIGG）、AI技术集团公司、Reliance全球集团公司（NASDAQ: RELI）、Melt公司、Ketdarina公司、3D MarkerJet公司（OTCMKTS: MRJT）、绿派集团有限公司、固神公司、FHT未来技术有限公司、Inspired Builders公司、Houmu控股有限公司（OTCMKTS: HOMU）、Born公司（OTCMKTS: MRJT）。长盛国际集团有限公司、索伦思股份有限公司（OTCMKTS: SOLS）、国资中宇资本控股有限公司（OTCMKTS: GZCC）、沧宝天下国际艺术品交易中心有限公司。Lazar先生目前担任PROMAX Investments LLC的顾问（自2022年7月以来），以及阿拉伯非洲一体化与发展委员会的无任所大使（自2022年3月以来）。
David Lazar,has served as the Chief Executive Officer of Custodian Ventures LLC, a company which specializes in assisting distressed public companies through custodianship, since February 2018, and Activist Investing LLC, an actively managed investment fund, since March 2018. Previously, Mr. Lazar served as Managing Partner at Zenith Partners International Inc., a boutique consulting firm, from July 2012 to April 2018. In his role as Chief Executive Officer of Custodian Ventures LLC, Mr. Lazar has successfully served as a custodian to numerous public companies across a wide range of industries, including without limitation, C2E Energy, Inc. (OTCMKTS: OOGI), China Botanic Pharmaceutical Inc. (OTCMKTS: CBPI), One 4 Art Ltd., Romulus Corp., Moveix, Inc., Arax Holdings Corp. (OTCMKTS: ARAT), ESP Resources, Inc. (OTCMKTS: ESPIQ), Adorbs, Inc., Exobox Technologies Corp. (OTCMKTS: EXBX), Petrone Worldwide, Inc. (OTCMKTS: PFWIQ), Superbox, Inc. (OTCMKTS: SBOX), Sino Green Land Corp. (OTCMKTS: SGLA), SIPP International Industries, Inc. (OTCMKTS: SIPN), Cereplast, Inc. (OTCMKTS: CERPQ), Energy 1 Corp. (OTCMKTS: EGOC), ForU Holdings, Inc. (OTCMKTS: FORU), China Yanyuan Yuhui National Education Group, Inc. (OTCMKTS: YYYH), Pan Global Corp. (OTCMKTS: PGLO), Shengtang International, Inc. (OTCMKTS: SHNL), Alternaturals, Inc. (OTCMKTS: ANAS), USA Recycling Industries, Inc. (OTCMKTS: USRI), Tele Group Corp., Xenoics Holdings, Inc. (OTCMKTS: XNNHQ), Richland Resources International Group, Inc. (OTCMKTS: RIGG), AI Technology Group, Inc., Reliance Global Group, Inc. (NASDAQ: RELI), Melt, Inc., Ketdarina Corp., 3D MarkerJet, Inc. (OTCMKTS: MRJT), Lvpai Group Ltd., Gushen, Inc., FHT Future Technology Ltd., Inspired Builders, Inc., Houmu Holdings Ltd. (OTCMKTS: HOMU), Born, Inc. (OTCMKTS: BRRN), Changsheng International Group Ltd., Sollensys Corp. (OTCMKTS: SOLS), Guozi Zhongyu Capital Holdings Co. (OTCMKTS: GZCC) and Cang Bao Tian Xia International Art Trade Center, Inc. Mr. Lazar currently serves as an Advisor to PROMAX Investments LLC, a position he has held since July 2022, and as an Ambassador at Large for the Arab African Council for Integration and Development, since March 2022. - David Lazar，自2018年2月起担任Custodian Ventures LLC（一家专门通过托管协助陷入困境的上市公司的公司）和Activist Investing LLC（一家积极管理的投资基金）的首席执行官。此前，Lazar先生于2012年7月至2018年4月担任精品咨询公司Zenith Partners International Inc.的管理合伙人。在担任Custodian Ventures LLC的首席执行官期间，Lazar先生成功地担任了多个行业众多上市公司的托管人，包括但不限于C2E Energy， Inc.(OTCMKTS: OOGI),China Botanic Pharmaceutical Inc.(OTCMKTS: CBPI),One 4 Art Ltd.,Romulus Corp.,Moveix, Inc.,Arax Holdings Corp.(OTCMKTS: ARAT),ESP Resources,Inc.(OTCMKTS: ESPIQ),Adorbs,Inc.,Exobox Technologies Corp. （OTCMKTS: CBPI）。EXBX)、Petrone Worldwide（OTCMKTS: PFWIQ）、Superbox（OTCMKTS: SBOX）、Sino Green Land corp（OTCMKTS: SGLA）、SIPP International Industries（OTCMKTS: SIPN）、Cereplast（OTCMKTS: CERPQ）、Energy 1 corp（OTCMKTS: EGOC）、ForU Holdings（OTCMKTS: ForU）、中国盐源宇辉国民教育集团（OTCMKTS: YYYH）、Pan Global corp （OTCMKTS: PGLO）、Shengtang International （OTCMKTS: SHNL）、Alternaturals,Inc(OTCMKTS:SBOX)：ANAS)、美国回收工业公司（OTCMKTS:USRI）、Tele集团公司、Xenoics控股公司（OTCMKTS: XNNHQ）、Richland资源国际集团公司（OTCMKTS: RIGG）、AI技术集团公司、Reliance全球集团公司（NASDAQ: RELI）、Melt公司、Ketdarina公司、3D MarkerJet公司（OTCMKTS: MRJT）、绿派集团有限公司、固神公司、FHT未来技术有限公司、Inspired Builders公司、Houmu控股有限公司（OTCMKTS: HOMU）、Born公司（OTCMKTS: MRJT）。长盛国际集团有限公司、索伦思股份有限公司（OTCMKTS: SOLS）、国资中宇资本控股有限公司（OTCMKTS: GZCC）、沧宝天下国际艺术品交易中心有限公司。Lazar先生目前担任PROMAX Investments LLC的顾问（自2022年7月以来），以及阿拉伯非洲一体化与发展委员会的无任所大使（自2022年3月以来）。
- David Lazar,has served as the Chief Executive Officer of Custodian Ventures LLC, a company which specializes in assisting distressed public companies through custodianship, since February 2018, and Activist Investing LLC, an actively managed investment fund, since March 2018. Previously, Mr. Lazar served as Managing Partner at Zenith Partners International Inc., a boutique consulting firm, from July 2012 to April 2018. In his role as Chief Executive Officer of Custodian Ventures LLC, Mr. Lazar has successfully served as a custodian to numerous public companies across a wide range of industries, including without limitation, C2E Energy, Inc. (OTCMKTS: OOGI), China Botanic Pharmaceutical Inc. (OTCMKTS: CBPI), One 4 Art Ltd., Romulus Corp., Moveix, Inc., Arax Holdings Corp. (OTCMKTS: ARAT), ESP Resources, Inc. (OTCMKTS: ESPIQ), Adorbs, Inc., Exobox Technologies Corp. (OTCMKTS: EXBX), Petrone Worldwide, Inc. (OTCMKTS: PFWIQ), Superbox, Inc. (OTCMKTS: SBOX), Sino Green Land Corp. (OTCMKTS: SGLA), SIPP International Industries, Inc. (OTCMKTS: SIPN), Cereplast, Inc. (OTCMKTS: CERPQ), Energy 1 Corp. (OTCMKTS: EGOC), ForU Holdings, Inc. (OTCMKTS: FORU), China Yanyuan Yuhui National Education Group, Inc. (OTCMKTS: YYYH), Pan Global Corp. (OTCMKTS: PGLO), Shengtang International, Inc. (OTCMKTS: SHNL), Alternaturals, Inc. (OTCMKTS: ANAS), USA Recycling Industries, Inc. (OTCMKTS: USRI), Tele Group Corp., Xenoics Holdings, Inc. (OTCMKTS: XNNHQ), Richland Resources International Group, Inc. (OTCMKTS: RIGG), AI Technology Group, Inc., Reliance Global Group, Inc. (NASDAQ: RELI), Melt, Inc., Ketdarina Corp., 3D MarkerJet, Inc. (OTCMKTS: MRJT), Lvpai Group Ltd., Gushen, Inc., FHT Future Technology Ltd., Inspired Builders, Inc., Houmu Holdings Ltd. (OTCMKTS: HOMU), Born, Inc. (OTCMKTS: BRRN), Changsheng International Group Ltd., Sollensys Corp. (OTCMKTS: SOLS), Guozi Zhongyu Capital Holdings Co. (OTCMKTS: GZCC) and Cang Bao Tian Xia International Art Trade Center, Inc. Mr. Lazar currently serves as an Advisor to PROMAX Investments LLC, a position he has held since July 2022, and as an Ambassador at Large for the Arab African Council for Integration and Development, since March 2022.
- Matthew C. McMurdo
-
Matthew C. McMurdo，现任McMurdo Law Group，LLC管理成员，该公司是一家公司和证券法律事务所，自2010年起。此前，麦克默多于2008年至2010年担任精品律师事务所Nannarone & McMurdo，LLP的合伙人。此外，麦克默多先生在2011年至2013年期间担任Berkley Asset Management LLC的总法律顾问，该公司是一家专注于机会主义和不良房地产资产的房地产基金的普通合伙人。麦克默多拥有利哈伊大学金融学学士学位和本杰明·N·卡多佐法学院以优异成绩获得的法学博士学位。
Matthew C. McMurdo,currently serves as Managing Member of McMurdo Law Group, LLC, a corporate and securities law practice, since 2010. Previously, Mr. McMurdo was a Partner at Nannarone & McMurdo, LLP, a boutique law firm, from 2008 to 2010. In addition, Mr. McMurdo served as General Counsel of Berkley Asset Management LLC, the general partner of a real estate fund focused on opportunistic and distressed real estate assets, from 2011 to 2013. Mr. McMurdo holds a B.S. in Finance from Lehigh University and a J.D., cum laude, from Benjamin N. Cardozo School of Law. - Matthew C. McMurdo，现任McMurdo Law Group，LLC管理成员，该公司是一家公司和证券法律事务所，自2010年起。此前，麦克默多于2008年至2010年担任精品律师事务所Nannarone & McMurdo，LLP的合伙人。此外，麦克默多先生在2011年至2013年期间担任Berkley Asset Management LLC的总法律顾问，该公司是一家专注于机会主义和不良房地产资产的房地产基金的普通合伙人。麦克默多拥有利哈伊大学金融学学士学位和本杰明·N·卡多佐法学院以优异成绩获得的法学博士学位。
- Matthew C. McMurdo,currently serves as Managing Member of McMurdo Law Group, LLC, a corporate and securities law practice, since 2010. Previously, Mr. McMurdo was a Partner at Nannarone & McMurdo, LLP, a boutique law firm, from 2008 to 2010. In addition, Mr. McMurdo served as General Counsel of Berkley Asset Management LLC, the general partner of a real estate fund focused on opportunistic and distressed real estate assets, from 2011 to 2013. Mr. McMurdo holds a B.S. in Finance from Lehigh University and a J.D., cum laude, from Benjamin N. Cardozo School of Law.
- David Natan
-
David Natan，现任Natan & Associates，LLC总裁兼首席执行官。Natan & Associates，LLC是一家咨询公司，为各行各业的上市公司和私营公司提供首席财务官服务。此外，纳坦先生自2020年4月起担任机载动力公司执行副总裁兼首席财务官。机载动力公司是一家私营航空运输公司。2010年2月至2020年5月，Natan先生担任ForceField Energy，Inc.（OTCMKTS：FNRG）首席执行官，该公司专注于太阳能行业和LED照明产品。从2002年2月至2007年11月，Natan先生担任药物开发服务公司PharmaNet Development Group，Inc.的报告执行副总裁兼首席财务官；从1995年6月至2002年2月，担任石油分析仪器、扬声器和扬声器部件制造商和营销商Global Technovations，Inc.的首席财务官兼副总裁。在此之前，纳坦先生在全球咨询公司德勤会计师事务所担任过各种职务，职责日益增加。Natan先生自2021年2月起担任食品和零食产品制造商、营销商和分销商Global Diversified Marketing Group，Inc.（OTCMKTS：GDMK）的董事会成员和审计委员会主席，自2022年2月起担任制药和营养补充剂公司Sunshine Biopharma, Inc.（纳斯达克股票代码：SBFM）的董事会成员和审计委员会主席。此前，Natan先生于2015年4月至2020年5月担任ForceField Energy公司董事会主席，并于1999年12月至2001年12月担任Global Technovations公司董事会成员。纳坦先生拥有波士顿大学经济学学士学位。
David Natan has served as Director at vario times since November 2023. He currently serves as President and Chief Executive Officer of Natan & Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of indtries, since 2007. Mr. Natan previoly served as a director of the Company from November 2023 to February 2025. He was re appointed as a director on April 29, 2025. From February 2010 to May 2020, Mr. Natan served as Chief Executive Officer of Force Field Energy, Inc. (OTCMKTS: FNRG), a company foced on the solar indtry and LED lighting products. From February 2002 to November 2007, Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer of Pharma Net Development Group, Inc., a drug development services company, and, from June 1995 to February 2002, as Chief Financial Officer and Vice President of Global Technovations, Inc., a manufacturer and marketer of oil analysis instruments and speakers and speaker components. Prior to tha, Mr. Natan served in vario roles of increasing responsibility with Deloitte & Touche LLP, a global consulting firm. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of Sunshine Biopharma, Inc. (Nasdaq: SBFM), a pharmaceutical and nutritional supplement company, since February 2022. Previoly, Mr. Natan has served as a director for the following public companies: Global Technovations, Forcefield Energy, Titan Pharmaceuticals (Nasdaq: TTNP), Vivakor Inc. (Nasdaq: VIVK), Net Brands Corp. (OTC: NBND), and OpGen Inc. (OTC: OPGN), and Cyclacel Pharmaceuticals (Nasdaq: CYCC). Mr. Natan holds a B.A. in Economics from Boston University. - David Natan，现任Natan & Associates，LLC总裁兼首席执行官。Natan & Associates，LLC是一家咨询公司，为各行各业的上市公司和私营公司提供首席财务官服务。此外，纳坦先生自2020年4月起担任机载动力公司执行副总裁兼首席财务官。机载动力公司是一家私营航空运输公司。2010年2月至2020年5月，Natan先生担任ForceField Energy，Inc.（OTCMKTS：FNRG）首席执行官，该公司专注于太阳能行业和LED照明产品。从2002年2月至2007年11月，Natan先生担任药物开发服务公司PharmaNet Development Group，Inc.的报告执行副总裁兼首席财务官；从1995年6月至2002年2月，担任石油分析仪器、扬声器和扬声器部件制造商和营销商Global Technovations，Inc.的首席财务官兼副总裁。在此之前，纳坦先生在全球咨询公司德勤会计师事务所担任过各种职务，职责日益增加。Natan先生自2021年2月起担任食品和零食产品制造商、营销商和分销商Global Diversified Marketing Group，Inc.（OTCMKTS：GDMK）的董事会成员和审计委员会主席，自2022年2月起担任制药和营养补充剂公司Sunshine Biopharma, Inc.（纳斯达克股票代码：SBFM）的董事会成员和审计委员会主席。此前，Natan先生于2015年4月至2020年5月担任ForceField Energy公司董事会主席，并于1999年12月至2001年12月担任Global Technovations公司董事会成员。纳坦先生拥有波士顿大学经济学学士学位。
- David Natan has served as Director at vario times since November 2023. He currently serves as President and Chief Executive Officer of Natan & Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of indtries, since 2007. Mr. Natan previoly served as a director of the Company from November 2023 to February 2025. He was re appointed as a director on April 29, 2025. From February 2010 to May 2020, Mr. Natan served as Chief Executive Officer of Force Field Energy, Inc. (OTCMKTS: FNRG), a company foced on the solar indtry and LED lighting products. From February 2002 to November 2007, Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer of Pharma Net Development Group, Inc., a drug development services company, and, from June 1995 to February 2002, as Chief Financial Officer and Vice President of Global Technovations, Inc., a manufacturer and marketer of oil analysis instruments and speakers and speaker components. Prior to tha, Mr. Natan served in vario roles of increasing responsibility with Deloitte & Touche LLP, a global consulting firm. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of Sunshine Biopharma, Inc. (Nasdaq: SBFM), a pharmaceutical and nutritional supplement company, since February 2022. Previoly, Mr. Natan has served as a director for the following public companies: Global Technovations, Forcefield Energy, Titan Pharmaceuticals (Nasdaq: TTNP), Vivakor Inc. (Nasdaq: VIVK), Net Brands Corp. (OTC: NBND), and OpGen Inc. (OTC: OPGN), and Cyclacel Pharmaceuticals (Nasdaq: CYCC). Mr. Natan holds a B.A. in Economics from Boston University.
- James R. McNab, Jr.
-
James R. McNab, Jr.，自2014年6月起担任JT Pharmaceuticals, Inc.（他创立的私有药物发现公司）的首席执行官。从2009年到2019年12月，他担任FirstString Research, Inc.（一家私营生物制药公司）的执行主席。McNab先生共同创立了几家私人控股公司，包括Sontra Medical Corporation（一家药物输送公司）和Parker Medical Associates（一家骨科和运动相关产品的制造商和全球供应商）。他获得戴维森学院（Davidson College）经济学学士学位和北卡罗来纳大学教堂山分校（University of North Carolina at Chapel Hill）工商管理硕士学位。McNab先生不会在年度会议上竞选连任董事。
James R. McNab, Jr.,has served since June 2014 as chief executive officer of JT Pharmaceuticals, Inc., a privately-held drug discovery company he founded. From 2009 until December 2019, Mr. McNab served as executive chairman of FirstString Research, Inc., a privately-held biopharmaceutical company. Mr. McNab has co-founded several privately-held companies, including Sontra Medical Corporation, a drug delivery company, and Parker Medical Associates, a manufacturer and worldwide supplier of orthopedic and sports-related products. He received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. Mr. McNab is not standing for re-election as a director at the Annual Meeting. - James R. McNab, Jr.，自2014年6月起担任JT Pharmaceuticals, Inc.（他创立的私有药物发现公司）的首席执行官。从2009年到2019年12月，他担任FirstString Research, Inc.（一家私营生物制药公司）的执行主席。McNab先生共同创立了几家私人控股公司，包括Sontra Medical Corporation（一家药物输送公司）和Parker Medical Associates（一家骨科和运动相关产品的制造商和全球供应商）。他获得戴维森学院（Davidson College）经济学学士学位和北卡罗来纳大学教堂山分校（University of North Carolina at Chapel Hill）工商管理硕士学位。McNab先生不会在年度会议上竞选连任董事。
- James R. McNab, Jr.,has served since June 2014 as chief executive officer of JT Pharmaceuticals, Inc., a privately-held drug discovery company he founded. From 2009 until December 2019, Mr. McNab served as executive chairman of FirstString Research, Inc., a privately-held biopharmaceutical company. Mr. McNab has co-founded several privately-held companies, including Sontra Medical Corporation, a drug delivery company, and Parker Medical Associates, a manufacturer and worldwide supplier of orthopedic and sports-related products. He received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. Mr. McNab is not standing for re-election as a director at the Annual Meeting.
- Marc Rubin
-
Marc Rubin，博士，自2011年10月起出任董事。现任Titan Pharmaceuticals, Inc.（TTNP： OTC BB）的董事局执行主席。从2007年10月至2009年1月担任其总裁兼首席执行官。曾担任Bayer Schering Pharma的全球研发部负责人，以及Bayer Healthcare执行委员会和Bayer Schering Pharm的管理委员会的成员，直到2007年2月。2006年6月Bayer Pharmaceuticals和Schering AG合并之前，自2003年10月加入Schering AG 起担任执行委员会的成员，以及Schering Berlin Inc.的董事长和Berlex Pharmaceuticals（Schering AG的一个部门）的总裁。从1990年到2003年8月，他受聘于GlaxoSmithKline，负责监督在美国、欧洲、亚洲和拉丁美洲的全球临床和商业发展项目。从2001年到2003年任职于GlaxoSmithKline，他是全球临床药理学与探索医学的高级副总裁。毕业于美国康奈尔大学医学院，获得医学博士学位，并且是内科与肿瘤内科和传染病亚专科委员会认证的一员。现任Curis Inc.（纳斯达克股票代码：CRIS）的董事会成员。曾担任Medarex, Inc.（现Bristol-Myers Squibb Company的附属公司）的董事。
Marc Rubin,a director since October 2011 and Chairman of the Board from January 2016 through May 2018, is Executive Chairman of the Board of Directors of Titan Pharmaceuticals, Inc. (TTNP: OTC BB) and served as its President and Chief Executive Officer from October 2007 to January 2009. Until February 2007, Dr. Rubin served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Executive Board of Schering AG since joining the company in October 2003, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until August 2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions of responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003 at GlaxoSmithKline, he was Senior Vice President of Global Clinical Pharmacology & Discovery Medicine. Dr. Rubin holds an M.D. from Cornell University Medical College and is board certified in internal medicine with subspecialties in medical oncology and infectious diseases. Dr. Rubin is a member of the Board of Directors of Curis Inc. (Nasdaq: CRIS) and formerly served on the Board of Directors of Medarex, Inc., now a subsidiary of Bristol-Myers Squibb Company. - Marc Rubin，博士，自2011年10月起出任董事。现任Titan Pharmaceuticals, Inc.（TTNP： OTC BB）的董事局执行主席。从2007年10月至2009年1月担任其总裁兼首席执行官。曾担任Bayer Schering Pharma的全球研发部负责人，以及Bayer Healthcare执行委员会和Bayer Schering Pharm的管理委员会的成员，直到2007年2月。2006年6月Bayer Pharmaceuticals和Schering AG合并之前，自2003年10月加入Schering AG 起担任执行委员会的成员，以及Schering Berlin Inc.的董事长和Berlex Pharmaceuticals（Schering AG的一个部门）的总裁。从1990年到2003年8月，他受聘于GlaxoSmithKline，负责监督在美国、欧洲、亚洲和拉丁美洲的全球临床和商业发展项目。从2001年到2003年任职于GlaxoSmithKline，他是全球临床药理学与探索医学的高级副总裁。毕业于美国康奈尔大学医学院，获得医学博士学位，并且是内科与肿瘤内科和传染病亚专科委员会认证的一员。现任Curis Inc.（纳斯达克股票代码：CRIS）的董事会成员。曾担任Medarex, Inc.（现Bristol-Myers Squibb Company的附属公司）的董事。
- Marc Rubin,a director since October 2011 and Chairman of the Board from January 2016 through May 2018, is Executive Chairman of the Board of Directors of Titan Pharmaceuticals, Inc. (TTNP: OTC BB) and served as its President and Chief Executive Officer from October 2007 to January 2009. Until February 2007, Dr. Rubin served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Executive Board of Schering AG since joining the company in October 2003, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until August 2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions of responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003 at GlaxoSmithKline, he was Senior Vice President of Global Clinical Pharmacology & Discovery Medicine. Dr. Rubin holds an M.D. from Cornell University Medical College and is board certified in internal medicine with subspecialties in medical oncology and infectious diseases. Dr. Rubin is a member of the Board of Directors of Curis Inc. (Nasdaq: CRIS) and formerly served on the Board of Directors of Medarex, Inc., now a subsidiary of Bristol-Myers Squibb Company.
高管简历
中英对照 | 中文 | 英文- Katherine Beebe DeVarney
Katherine Beebe DeVarney于2007年2月加入泰坦，自2020年10月起担任总裁兼首席运营官。此前，她曾担任首席科学官。她自2019年12月起担任董事会成员。Beebe Devarney博士在我们公司工作的13年中，担任过各种科学和医疗研究与开发职务，主要负责监督我们的产品研究与开发、监管事务和医疗事务。她拥有25年的制药行业神经科学家经验，包括任职SmithKline Beecham公司、GlaxoSmithKline公司、Merck公司、Corcept Therapeutics公司，并不断被提拔。在她的制药职业生涯之前，Beebe Devarney博士是一位以医院为基础的临床医生，在学术医学领域工作了10年。她在乔治梅森大学（George Mason University）获得临床神经心理学博士学位，并在研究生院和宾夕法尼亚大学（University of Pennsylvania）完成了两年的博士后奖学金。
Katherine Beebe DeVarney,joined Titan in February 2007 and currently serves as Titan Pharmaceuticals, Inc. President and Chief Operating Officer since October 2020. She has been a member of the Board since December 2019. During her 15 years with Titan Pharmaceuticals, Inc. , she has served in various scientific and medical research and development capacities, with primary responsibility for oversight of Titan Pharmaceuticals, Inc. product research and development, Regulatory Affairs, and Medical Affairs. Dr. Beebe DeVarney has 24 years of experience as a Neuroscientist in the pharmaceutical industry, including positions of increasing responsibility with SmithKline Beecham, GlaxoSmithKline, Merck, and Corcept Therapeutics. Prior to her pharmaceutical career, Dr. Beebe DeVarney was a hospital-based clinician and worked in academic medicine for 10 years. She received her Ph.D. in Clinical Neuropsychology from George Mason University, and completed a two-year post-doctoral fellowship at Graduate Hospital and the University of Pennsylvania.- Katherine Beebe DeVarney于2007年2月加入泰坦，自2020年10月起担任总裁兼首席运营官。此前，她曾担任首席科学官。她自2019年12月起担任董事会成员。Beebe Devarney博士在我们公司工作的13年中，担任过各种科学和医疗研究与开发职务，主要负责监督我们的产品研究与开发、监管事务和医疗事务。她拥有25年的制药行业神经科学家经验，包括任职SmithKline Beecham公司、GlaxoSmithKline公司、Merck公司、Corcept Therapeutics公司，并不断被提拔。在她的制药职业生涯之前，Beebe Devarney博士是一位以医院为基础的临床医生，在学术医学领域工作了10年。她在乔治梅森大学（George Mason University）获得临床神经心理学博士学位，并在研究生院和宾夕法尼亚大学（University of Pennsylvania）完成了两年的博士后奖学金。
- Katherine Beebe DeVarney,joined Titan in February 2007 and currently serves as Titan Pharmaceuticals, Inc. President and Chief Operating Officer since October 2020. She has been a member of the Board since December 2019. During her 15 years with Titan Pharmaceuticals, Inc. , she has served in various scientific and medical research and development capacities, with primary responsibility for oversight of Titan Pharmaceuticals, Inc. product research and development, Regulatory Affairs, and Medical Affairs. Dr. Beebe DeVarney has 24 years of experience as a Neuroscientist in the pharmaceutical industry, including positions of increasing responsibility with SmithKline Beecham, GlaxoSmithKline, Merck, and Corcept Therapeutics. Prior to her pharmaceutical career, Dr. Beebe DeVarney was a hospital-based clinician and worked in academic medicine for 10 years. She received her Ph.D. in Clinical Neuropsychology from George Mason University, and completed a two-year post-doctoral fellowship at Graduate Hospital and the University of Pennsylvania.
- David Lazar
David Lazar，自2018年2月起担任Custodian Ventures LLC（一家专门通过托管协助陷入困境的上市公司的公司）和Activist Investing LLC（一家积极管理的投资基金）的首席执行官。此前，Lazar先生于2012年7月至2018年4月担任精品咨询公司Zenith Partners International Inc.的管理合伙人。在担任Custodian Ventures LLC的首席执行官期间，Lazar先生成功地担任了多个行业众多上市公司的托管人，包括但不限于C2E Energy， Inc.(OTCMKTS: OOGI),China Botanic Pharmaceutical Inc.(OTCMKTS: CBPI),One 4 Art Ltd.,Romulus Corp.,Moveix, Inc.,Arax Holdings Corp.(OTCMKTS: ARAT),ESP Resources,Inc.(OTCMKTS: ESPIQ),Adorbs,Inc.,Exobox Technologies Corp. （OTCMKTS: CBPI）。EXBX)、Petrone Worldwide（OTCMKTS: PFWIQ）、Superbox（OTCMKTS: SBOX）、Sino Green Land corp（OTCMKTS: SGLA）、SIPP International Industries（OTCMKTS: SIPN）、Cereplast（OTCMKTS: CERPQ）、Energy 1 corp（OTCMKTS: EGOC）、ForU Holdings（OTCMKTS: ForU）、中国盐源宇辉国民教育集团（OTCMKTS: YYYH）、Pan Global corp （OTCMKTS: PGLO）、Shengtang International （OTCMKTS: SHNL）、Alternaturals,Inc(OTCMKTS:SBOX)：ANAS)、美国回收工业公司（OTCMKTS:USRI）、Tele集团公司、Xenoics控股公司（OTCMKTS: XNNHQ）、Richland资源国际集团公司（OTCMKTS: RIGG）、AI技术集团公司、Reliance全球集团公司（NASDAQ: RELI）、Melt公司、Ketdarina公司、3D MarkerJet公司（OTCMKTS: MRJT）、绿派集团有限公司、固神公司、FHT未来技术有限公司、Inspired Builders公司、Houmu控股有限公司（OTCMKTS: HOMU）、Born公司（OTCMKTS: MRJT）。长盛国际集团有限公司、索伦思股份有限公司（OTCMKTS: SOLS）、国资中宇资本控股有限公司（OTCMKTS: GZCC）、沧宝天下国际艺术品交易中心有限公司。Lazar先生目前担任PROMAX Investments LLC的顾问（自2022年7月以来），以及阿拉伯非洲一体化与发展委员会的无任所大使（自2022年3月以来）。
David Lazar,has served as the Chief Executive Officer of Custodian Ventures LLC, a company which specializes in assisting distressed public companies through custodianship, since February 2018, and Activist Investing LLC, an actively managed investment fund, since March 2018. Previously, Mr. Lazar served as Managing Partner at Zenith Partners International Inc., a boutique consulting firm, from July 2012 to April 2018. In his role as Chief Executive Officer of Custodian Ventures LLC, Mr. Lazar has successfully served as a custodian to numerous public companies across a wide range of industries, including without limitation, C2E Energy, Inc. (OTCMKTS: OOGI), China Botanic Pharmaceutical Inc. (OTCMKTS: CBPI), One 4 Art Ltd., Romulus Corp., Moveix, Inc., Arax Holdings Corp. (OTCMKTS: ARAT), ESP Resources, Inc. (OTCMKTS: ESPIQ), Adorbs, Inc., Exobox Technologies Corp. (OTCMKTS: EXBX), Petrone Worldwide, Inc. (OTCMKTS: PFWIQ), Superbox, Inc. (OTCMKTS: SBOX), Sino Green Land Corp. (OTCMKTS: SGLA), SIPP International Industries, Inc. (OTCMKTS: SIPN), Cereplast, Inc. (OTCMKTS: CERPQ), Energy 1 Corp. (OTCMKTS: EGOC), ForU Holdings, Inc. (OTCMKTS: FORU), China Yanyuan Yuhui National Education Group, Inc. (OTCMKTS: YYYH), Pan Global Corp. (OTCMKTS: PGLO), Shengtang International, Inc. (OTCMKTS: SHNL), Alternaturals, Inc. (OTCMKTS: ANAS), USA Recycling Industries, Inc. (OTCMKTS: USRI), Tele Group Corp., Xenoics Holdings, Inc. (OTCMKTS: XNNHQ), Richland Resources International Group, Inc. (OTCMKTS: RIGG), AI Technology Group, Inc., Reliance Global Group, Inc. (NASDAQ: RELI), Melt, Inc., Ketdarina Corp., 3D MarkerJet, Inc. (OTCMKTS: MRJT), Lvpai Group Ltd., Gushen, Inc., FHT Future Technology Ltd., Inspired Builders, Inc., Houmu Holdings Ltd. (OTCMKTS: HOMU), Born, Inc. (OTCMKTS: BRRN), Changsheng International Group Ltd., Sollensys Corp. (OTCMKTS: SOLS), Guozi Zhongyu Capital Holdings Co. (OTCMKTS: GZCC) and Cang Bao Tian Xia International Art Trade Center, Inc. Mr. Lazar currently serves as an Advisor to PROMAX Investments LLC, a position he has held since July 2022, and as an Ambassador at Large for the Arab African Council for Integration and Development, since March 2022.- David Lazar，自2018年2月起担任Custodian Ventures LLC（一家专门通过托管协助陷入困境的上市公司的公司）和Activist Investing LLC（一家积极管理的投资基金）的首席执行官。此前，Lazar先生于2012年7月至2018年4月担任精品咨询公司Zenith Partners International Inc.的管理合伙人。在担任Custodian Ventures LLC的首席执行官期间，Lazar先生成功地担任了多个行业众多上市公司的托管人，包括但不限于C2E Energy， Inc.(OTCMKTS: OOGI),China Botanic Pharmaceutical Inc.(OTCMKTS: CBPI),One 4 Art Ltd.,Romulus Corp.,Moveix, Inc.,Arax Holdings Corp.(OTCMKTS: ARAT),ESP Resources,Inc.(OTCMKTS: ESPIQ),Adorbs,Inc.,Exobox Technologies Corp. （OTCMKTS: CBPI）。EXBX)、Petrone Worldwide（OTCMKTS: PFWIQ）、Superbox（OTCMKTS: SBOX）、Sino Green Land corp（OTCMKTS: SGLA）、SIPP International Industries（OTCMKTS: SIPN）、Cereplast（OTCMKTS: CERPQ）、Energy 1 corp（OTCMKTS: EGOC）、ForU Holdings（OTCMKTS: ForU）、中国盐源宇辉国民教育集团（OTCMKTS: YYYH）、Pan Global corp （OTCMKTS: PGLO）、Shengtang International （OTCMKTS: SHNL）、Alternaturals,Inc(OTCMKTS:SBOX)：ANAS)、美国回收工业公司（OTCMKTS:USRI）、Tele集团公司、Xenoics控股公司（OTCMKTS: XNNHQ）、Richland资源国际集团公司（OTCMKTS: RIGG）、AI技术集团公司、Reliance全球集团公司（NASDAQ: RELI）、Melt公司、Ketdarina公司、3D MarkerJet公司（OTCMKTS: MRJT）、绿派集团有限公司、固神公司、FHT未来技术有限公司、Inspired Builders公司、Houmu控股有限公司（OTCMKTS: HOMU）、Born公司（OTCMKTS: MRJT）。长盛国际集团有限公司、索伦思股份有限公司（OTCMKTS: SOLS）、国资中宇资本控股有限公司（OTCMKTS: GZCC）、沧宝天下国际艺术品交易中心有限公司。Lazar先生目前担任PROMAX Investments LLC的顾问（自2022年7月以来），以及阿拉伯非洲一体化与发展委员会的无任所大使（自2022年3月以来）。
- David Lazar,has served as the Chief Executive Officer of Custodian Ventures LLC, a company which specializes in assisting distressed public companies through custodianship, since February 2018, and Activist Investing LLC, an actively managed investment fund, since March 2018. Previously, Mr. Lazar served as Managing Partner at Zenith Partners International Inc., a boutique consulting firm, from July 2012 to April 2018. In his role as Chief Executive Officer of Custodian Ventures LLC, Mr. Lazar has successfully served as a custodian to numerous public companies across a wide range of industries, including without limitation, C2E Energy, Inc. (OTCMKTS: OOGI), China Botanic Pharmaceutical Inc. (OTCMKTS: CBPI), One 4 Art Ltd., Romulus Corp., Moveix, Inc., Arax Holdings Corp. (OTCMKTS: ARAT), ESP Resources, Inc. (OTCMKTS: ESPIQ), Adorbs, Inc., Exobox Technologies Corp. (OTCMKTS: EXBX), Petrone Worldwide, Inc. (OTCMKTS: PFWIQ), Superbox, Inc. (OTCMKTS: SBOX), Sino Green Land Corp. (OTCMKTS: SGLA), SIPP International Industries, Inc. (OTCMKTS: SIPN), Cereplast, Inc. (OTCMKTS: CERPQ), Energy 1 Corp. (OTCMKTS: EGOC), ForU Holdings, Inc. (OTCMKTS: FORU), China Yanyuan Yuhui National Education Group, Inc. (OTCMKTS: YYYH), Pan Global Corp. (OTCMKTS: PGLO), Shengtang International, Inc. (OTCMKTS: SHNL), Alternaturals, Inc. (OTCMKTS: ANAS), USA Recycling Industries, Inc. (OTCMKTS: USRI), Tele Group Corp., Xenoics Holdings, Inc. (OTCMKTS: XNNHQ), Richland Resources International Group, Inc. (OTCMKTS: RIGG), AI Technology Group, Inc., Reliance Global Group, Inc. (NASDAQ: RELI), Melt, Inc., Ketdarina Corp., 3D MarkerJet, Inc. (OTCMKTS: MRJT), Lvpai Group Ltd., Gushen, Inc., FHT Future Technology Ltd., Inspired Builders, Inc., Houmu Holdings Ltd. (OTCMKTS: HOMU), Born, Inc. (OTCMKTS: BRRN), Changsheng International Group Ltd., Sollensys Corp. (OTCMKTS: SOLS), Guozi Zhongyu Capital Holdings Co. (OTCMKTS: GZCC) and Cang Bao Tian Xia International Art Trade Center, Inc. Mr. Lazar currently serves as an Advisor to PROMAX Investments LLC, a position he has held since July 2022, and as an Ambassador at Large for the Arab African Council for Integration and Development, since March 2022.